Medical Dialogues
  • Dermatology
Sign in Signup
This site is intended for healthcare professionals only
Sign in Signup
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
Medical Dialogues
  • Medical News
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Medical Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
  • MDTV
      • Anesthesia
      • CTVS
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • Diet and nutrition
      • ENT
      • Gastroenterology
      • Health Dialogues
      • Health News today
      • Health Shorts
      • Health Updates
      • Health video of the day
      • Laboratory Medicine
      • Latest Videos
      • Latest Webinars
      • MD shorts
      • Medical News Today
      • Medical Updates
      • Medical Video of the day
      • Medicine
      • Nephrology
      • Neurology and Neurosurgery
      • Obstetrics and Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics & Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Top Videos
      • Urology
This site is intended for healthcare professionals only
Sign InRegister
Medical Dialogues
Sign inRegister
  • Home
  • Medical news
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Medical Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
  • Case of the Day
  • Editorial
  • Home
  • Nephrology
  • Nephrology News
  • Voclosporin Shows...

Voclosporin Shows Promising Results for Lupus Nephritis: Interim Analysis of AURORA 2

MD BureauBy MD BureauPublished On 2022-01-07T09:00:42+05:30  |  Updated On 2022-01-07T09:01:08+05:30
Voclosporin Shows Promising Results for Lupus Nephritis: Interim Analysis of AURORA 2

Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in 2 pivotal trials in adult patients with lupus nephritis (LN). AURORA 2 is a 2-year extension study, AURORA 1. Based on AURORA 1 study findings, the FDA approved voclosporin for the treatment of lupus nephritis. Recent interim analysis of the AURORA 2 trial shows a meaningful effect in lupus nephritis with no...

Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in 2 pivotal trials in adult patients with lupus nephritis (LN). AURORA 2 is a 2-year extension study, AURORA 1. Based on AURORA 1 study findings, the FDA approved voclosporin for the treatment of lupus nephritis. Recent interim analysis of the AURORA 2 trial shows a meaningful effect in lupus nephritis with no change in mean eGFR at 30 months. The study findings were presented at the ACR Convergence 2021 virtual meeting and published in the journal American College of Rheumatology.

Previous study findings from the Phase 3 AURORA 1 and Phase 2 AURA-LV studies showed that the addition of voclosporin with mycophenolate mofetil (MMF) and low-dose steroids, significantly increased the renal response rate and reduced proteinuria in patients with LN at 48 weeks in AURA-LV and 52 weeks in AURORA 1. In this 2-year extension study, Dr Amit Saxena and his team further evaluated the effect of voclosporin with placebo for the achievement of complete renal response used in combination with mycophenolate and low-dose steroids.

AURORA 2 is a 2-year, blinded, controlled extension study of AURORA 1, with exposure up to 30 months (12 months from AURORA 1 and up to an additional 18 months in AURORA 2). Patients with systemic lupus erythematosus who completed AURORA 1 (n=216) continued in their same treatment group, with 116 in the voclosporin group (23.7 mg BID) and 100 in the placebo group in combination with MMF (1 g BID) and low-dose oral steroids. As of this interim analysis, 90 and 78 patients, respectively, had received 30 months of total treatment. The researchers evaluated urine protein creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR).

Key Findings of the Study Were:

  • At baseline, the UPCR at pre-treatment (AURORA 1) was 3.94 mg/mg in the voclosporin arm (n=116) and 3.87 mg/mg in the control arm (n=100).
  • Upon analysis, they found that the mean change in UPCR from pre-treatment baseline to month 30 was -3.32 mg/mg for the voclosporin arm (n=90) and -2.55 mg/mg for the control arm (n=78).
  • They also noted a small, expected and early decrease in mean eGFR in the voclosporin arm in the first 4 weeks of treatment in AURORA 1, after which eGFR remained stable through month 30.
  • They found no new unexpected adverse events reported in patients who continued voclosporin treatment compared to control-treated patients.
  • They reported a total of 6 and 10 events of coronavirus (COVID-19) infection in the voclosporin and control arms, among which 2 and 6 events were serious coronavirus infections.

The authors concluded, "Patients in the voclosporin treatment arm maintained meaningful reductions in proteinuria with no change in mean eGFR at 30 months of treatment. Additional AURORA 2 efficacy and safety data will be provided at the conclusion of the study."

For further information:

Saxena A, Mela C, Coeshall A. Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/voclosporin-for-lupus-nephritis-interim-analysis-of-the-aurora-2-extension-study/. Accessed November 12, 2021


Voclosporin AURORA 2 Interim Analysis lupus nephritis AURA-LV study AURORA 1 mycophenolate mofetil low dose steroid ACR Convergence 2021 American College of Rheumatology 30 months 
Article Source :  American College of Rheumatology
MD Bureau
MD Bureau

    Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Air pollution and allergic rhinitis: Understanding the invisible, yet the inevitable  connection

    Air pollution and allergic rhinitis: Understanding the invisible, yet the inevitable connection

    Treatment challenges in managing Gastroparesis related to PPI Use: Analyzing scope of Probiotics

    Treatment challenges in managing Gastroparesis related to PPI Use: Analyzing scope of Probiotics

    Review: Efficacy of Antiviral Agents Against  Omicron Subvariant BA.2

    Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    View All

    Journal Club Today

    Health News Today

    Health Bulletin 20/May/2022

    Health Bulletin 20/May/2022

    View All
    © 2019 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X